Clinical trials: Single Dose
Healthy
Safety, Tolerability and Pharmacokinetics of Oral BIBP 5371 CL in Healthy Male and Female Volunteers
Safety, tolerability and pharmacokinetics (including comparisons of different formulations and investigation of food effect)
- Trial name
- NCT02256709
- Testing
- BIBP 5371 CL tablet, BIBP 5371 CL solution, High fat, high caloric breakfast
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Dry Eye
Safety, Tolerability and Pharmacokinetics of 0.5% and 2.5% Cis-UCA Eye Drops in Adult Healthy Volunteers (Phase I)
The purpose of this two-part study is to evaluate safety, tolerability and pharmacokinetics of 0.5% and 2.5% cis-UCA eye drops in comparison to placebo in adult healthy volunteers.
- Trial name
- NCT01476332
- Testing
- cis-urocanic acid 0,5% eye drops, cis-urocanic acid 2.5% eye drops
- Where
- Finland
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Laurantis Pharma, Ltd.
Breast Cancer, Early-Stage Breast Carcinoma
SOLIS: Single-Dose Radiotherapy With Omission of Lumpectomy for Intact Small Breast Cancers
SOLIS is a prospective, single-arm, single-institution pilot trial evaluating single-fraction stereotactic radiotherapy (24 Gy to the planning target volume with a simultaneous integrated boost of 30 Gy to the clinical target…
- Conditions
- Breast Cancer, Early-Stage Breast Carcinoma, Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
- Trial name
- SOLIS (NCT07844759)
- Testing
- Stereotactic Radiation Therapy, Endocrine Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Renaissance Institute of Precision Oncology and Radiosurgery
Multiple Myeloma
Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients
BKT-140 drug substance is a highly selective chemokine receptor (CXCR4) antagonist, which is developed by Biokine as a novel therapy for Multiple Myeloma (MM, a type of blood cancer).
- Trial name
- NCT01010880
- Testing
- BKT140
- Where
- 2 sites in Israel
- Volunteers
- 16 people
- Sponsor
- Biokine Therapeutics Ltd
Malaria, Plasmodium Infections
Effectiveness of Mass Drug Administration for Reducing Seasonal Malaria Transmission in Zanzibar
The overall aim of this study is to determine the effectiveness of two rounds of mass drug administration (MDA) with dihydroartemisinin-piperaquine (DHAp) + single low dose (SLD) primaquine for reducing seasonal malaria…
- Trial name
- MaDrAZ (NCT02721186)
- Testing
- MDA with DHAp and SLD Primaquine
- Where
- Tanzania
- Volunteers
- 22,500 people, healthy volunteers welcome
- Sponsor
- Ulrika Morris
Healthy Adults
A Study（Phase I）of GS3-007a Dry Suspension in Healthy Chinese Adults
This study consists of two parts: the first part is a single-dose escalating（SAD） and food effect （FE）study, and the second part is a multiple-dose (14-day) escalating(MAD) study.
- Trial name
- NCT07473570
- Testing
- GS3-007a for Suspension
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Contraception, Menopause
Safety, Tolerability and Pharmacokinetics of Estetrol (E4) After Single and Multiple Oral Doses in Healthy Female Volunteers
Estetrol (E4) is being developed in two indications supporting women health care: first E4 is combined with a progestin, [drospirenone (DRSP)] and is used as a new combined oral contraceptive (COC) for the prevention of pregnancy…
- Trial name
- NCT03075956
- Testing
- 5 mg E4 single-dose, 15 mg E4 single-dose, 45 mg E4 single-dose
- Where
- Bulgaria
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Estetra
Rheumatoid Arthritis
BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis
Phase I study designed to determine the safety and tolerability of a single dose of BIIB023 administered intravenously versus placebo to subjects with RA.
- Trial name
- NCT00771329
- Testing
- BIIB023
- Where
- 6 sites in United States, Russia
- Volunteers
- 53 people
- Sponsor
- Biogen
Optimal Gastrointestinal Absorption of Omega-3
A Study to Determine Optimal Absorption of Single Dose Omega-3
This is a randomised three-way cross over study comparing the optimal absorption of a single dose of fish oil using 3 different forms to one another on increasing blood concentrations of fatty acids in 24 healthy adult…
- Trial name
- NCT05491759
- Testing
- Product 1 - AquaCelle Fish Oil Triglyceride, Product 2 - AquaCelle Fish Oil Ethyl Ester, Product 3 - Standard Fish Oil Triglyceride
- Where
- Australia
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- RDC Clinical Pty Ltd
Healthy
A Thorough QT Study of Aticaprant (JNJ-67953964) in Healthy Adult Participants
The purpose of this study is to assess the effects of aticaprant on QT/ QT interval corrected for heart rate (HR) (QTc) intervals and electrocardiogram (ECG) morphology at therapeutic and supratherapeutic exposures in healthy…
- Trial name
- NCT05387759
- Testing
- Aticaprant Supratherapeutic Dose, Aticaprant Therapeutic Dose, Moxifloxacin
- Where
- Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Smoking Cessation
A First-in-Human Study of SBP-9330 in Healthy Subjects
This is a single center, first-in-human, randomized, double-blind, placebo-controlled, Single-Ascending Dose (SAD) / Multiple-Ascending Dose (MAD) study incorporating a food-effect cohort.
- Trial name
- NCT04948827
- Testing
- SBP-9330
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Camino Pharma, LLC
Diabetes Mellitus, Type 2
A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics
The aim of this study is to verify whether a significant decrease in glucose levels can be achieved with the HM74A agonist GSK256073 in type 2 diabetic patients.
- Trial name
- NCT01147861
- Testing
- GSK256073
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- GlaxoSmithKline
Healthy
AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy Subjects
Phase 1, open label, single dose, 3 way crossover study to evaluate the bioavailability of a solid dose formulation of PF 04965842 relative to a suspension formulation under fasting conditions and the effect of food on the…
- Trial name
- NCT02163161
- Testing
- PF-04965842, PF- 04965842
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension
Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine
This study will compare the bioavailability and pharmacokinetics of the 0.5 mg, 1 mg and 2.5 mg treprostinil diethanolamine tablet strengths in healthy volunteers.
- Trial name
- NCT01153386
- Testing
- Treprostinil diethanolamine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- United Therapeutics
Healthy Individuals, Bioequivalence Study
Bioequivalence Study of Mofest® 400mg (Moxifloxacin) Tablet With Avelox® 400mg (Moxifloxacin) Tablet in Healthy Pakistani Subjects
Single oral dose, of test and reference Tablet will be administered to healthy volunteers, after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-points.
- Trial name
- BE (NCT04873570)
- Testing
- Moxifloxacin 400mg
- Where
- Pakistan
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Karachi
Chronic Hepatitis c
The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects
The Safety, Tolerability and Pharmacokinetic Study of Chronic Hepatitis C Treatment Drug Yimitasvir in Healthy Adults Subjects.
- Trial name
- NCT03462173
- Testing
- yimitasvir
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Alzheimer's Disease
A Safety Study of LY2886721 Single Doses in Healthy Subjects
This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2886721 single doses, how the body handles the drug, and the drug's effect on the body.
- Trial name
- NCT01133405
- Testing
- LY2886721
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Psoriasis Vulgaris
LEO 32731 - A Phase I Study in Healthy Subjects
LEO 32731 ("Study Drug") is an investigational drug which is being developed by LEO Pharma A/S ("the Sponsor") for treatment of psoriasis.
- Trial name
- NCT02514694
- Testing
- LEO32731
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Asthma
Symbicort Onset of Action 1
The purpose of this study is to compare the early onset of effect of Symbicort compared to Advair Diskus and Ventolin in adults with asthma
- Trial name
- NCT00646620
- Testing
- budesonide/formoterol (Symbicort), fluticasone/salmeterol (Advair Diskus), albuterol (Ventolin)
- Volunteers
- 48 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis (RA), Inflammatory Bowel Disease - IBD1
Phase I Clinical Study of ZL-82 Tablets
ZL-82 is an oral janus kinase (JAK) inhibitor. In vitro biological mass spectrometry identification test proves that ZL-82 can selectively and irreversibly inhibit JAK3.
- Trial name
- NCT06055023
- Testing
- ZL-82 12.5mg, ZL-82 25mg, ZL-82 50mg
- Where
- China
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.